	US 12,440,442 B2
	Thermogelling nanoemulsions for pharmaceutical manufacturing
Liang-Hsun Chen, Cambridge, MA (US); and Patrick S. Doyle, Cambridge, MA (US)
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,696.
Claims priority of provisional application 63/153,472, filed on Feb. 25, 2021.
Prior Publication US 2022/0265554 A1, Aug. 25, 2022
Int. Cl. A61K 9/107 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)

CPC A61K 9/1075 (2013.01) [A61K 9/006 (2013.01); A61K 9/16 (2013.01); A61K 9/2095 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)]

57 Claims

1. A composition comprising nanoparticles, wherein the nanoparticles comprise nanocrystals encapsulated in thermogelling polymers, and wherein the nanocrystals comprise hydrophobic therapeutic, diagnostic, prophylactic agents, or a combination thereof, wherein forming the nanoparticles involves heating a nanoemulsion comprising:

(i) a dispersed oil phase that comprises the hydrophobic therapeutic, diagnostic, prophylactic agents, or the combination thereof, and

(ii) a continuous water phase that comprises the thermogelling polymers.